Methods and materials for identifying and treating autoimmune gfap astrocytopathy
AssigneeMayo Foundation for Medical Education and Research
InventorsVanda A. Lennon, Andrew McKeon, Boyan Fang, Shannon Hinson, Thomas J. Kryzer
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).
Claims19
1-4. (canceled)
A method for treating an autoimmune GFAP astrocytopathy in a human, wherein said method comprises:
- (a) identifying said human as having GFAP-specific IgG, and
- (b) administering a steroid compound to said human.
A method for treating an autoimmune GFAP astrocytopathy, wherein said method comprises administering a steroid compound to a human identified as having GFAP-specific IgG.
10-15. (canceled)
A kit comprising:
- (a) a first antigen source comprising a GFAP polypeptide and lacking NMDA-R and AQP4 polypeptides,
- (b) a second antigen source comprising a NMDA-R or AQP4 polypeptide and lacking GFAP polypeptides, and
- (c) an anti-human IgG antibody.
Dependencies are inferred from the claim text.